Pioneer Investment Management Inc. decreased its position in Zoetis Inc. (NYSE:ZTS) by 6.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,416,657 shares of the company’s stock after selling 94,315 shares during the period. Pioneer Investment Management Inc. owned approximately 0.29% of Zoetis worth $88,371,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of the company. Guardian Life Insurance Co. of America raised its position in shares of Zoetis by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 1,905 shares of the company’s stock worth $102,000 after buying an additional 13 shares in the last quarter. Sii Investments Inc. WI increased its stake in Zoetis by 0.3% in the first quarter. Sii Investments Inc. WI now owns 7,161 shares of the company’s stock worth $383,000 after buying an additional 23 shares during the last quarter. Argent Trust Co increased its stake in Zoetis by 0.8% in the first quarter. Argent Trust Co now owns 4,132 shares of the company’s stock worth $221,000 after buying an additional 32 shares during the last quarter. Ironwood Investment Management LLC increased its stake in shares of Zoetis by 0.7% in the second quarter. Ironwood Investment Management LLC now owns 6,870 shares of the company’s stock valued at $429,000 after buying an additional 48 shares in the last quarter. Finally, CENTRAL TRUST Co increased its position in Zoetis by 1.9% in the first quarter. CENTRAL TRUST Co now owns 2,664 shares of the company’s stock valued at $142,000 after buying an additional 49 shares in the last quarter. Hedge funds and other institutional investors own 92.70% of the company’s stock.
Zoetis Inc. (NYSE ZTS) traded down 0.25% during midday trading on Friday, reaching $60.75. 1,513,092 shares of the company were exchanged. The company has a market capitalization of $29.71 billion, a price-to-earnings ratio of 34.34 and a beta of 1.02. Zoetis Inc. has a 52-week low of $46.86 and a 52-week high of $63.85. The company has a 50 day moving average of $61.95 and a 200-day moving average of $58.24.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 8th. The company reported $0.53 EPS for the quarter, hitting the consensus estimate of $0.53. The company had revenue of $1.27 billion during the quarter, compared to analyst estimates of $1.27 billion. Zoetis had a return on equity of 62.49% and a net margin of 17.50%. The business’s revenue was up 5.0% on a year-over-year basis. During the same quarter last year, the firm earned $0.49 EPS. On average, equities research analysts anticipate that Zoetis Inc. will post $2.34 earnings per share for the current fiscal year.
ZTS has been the topic of several recent analyst reports. Jefferies Group LLC raised their price target on shares of Zoetis from $65.00 to $70.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Cantor Fitzgerald set a $75.00 price target on shares of Zoetis and gave the stock a “buy” rating in a research note on Monday. Argus reaffirmed a “buy” rating and issued a $69.00 price target (up previously from $60.00) on shares of Zoetis in a research note on Tuesday, May 30th. CL King assumed coverage on shares of Zoetis in a report on Friday, May 26th. They set a “buy” rating and a $71.00 target price on the stock. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $65.00 target price (up from $62.00) on shares of Zoetis in a report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twelve have assigned a buy rating to the company. Zoetis has a consensus rating of “Buy” and an average target price of $64.78.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.